Cyclacel Pharmaceuticals Stock Price - CYCC

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Pre-Market
Last Trade
Last $ 0.80 ▲ 0.02 (2.56%)
Company Name Stock Ticker Symbol Market Type
Cyclacel Pharmaceuticals Inc CYCC NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 0.7799 0.00 0.00 0.00 0.7799 07:52:44
Bid Price Ask Price Spread Spread % News
0.80 0.90 0.10 11.11% - -
Stock Trades Traded Volume Average Volume 52 Week Range
4 3,151 393,630 0.2813 - 1.40
Last Trade Time Type Quantity Stock Price Currency
07:59:39 formt 200 $ 0.7999 USD

Cyclacel Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 13.41M 17.20M $ -7.29M -0.63 - 16.20M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Cyclacel Pharmaceuticals News

Loading Messages....

Latest CYCC Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CYCC Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.7180.810.700.7870719305,8710.06198.62%
1 Month0.560.9798690.53110.7836803411,8220.219939.27%
3 Months0.42330.9798690.35210.6945841271,5780.356684.24%
6 Months0.55470.9798690.28130.6365674156,3570.225240.6%
1 Year0.72371.400.28130.781472411,6040.05627.77%
3 Years5.0410.900.28132.42363,954-4.26-84.53%
5 Years0.6210.900.28132.40355,8130.159925.79%

Cyclacel Pharmaceuticals Description

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. The company earns the majority of its revenue from the United Kingdom.


Your Recent History
NASDAQ
CYCC
Cyclacel P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.